PIK3CA and colorectal carcinoma: As shown in Fig. 7f, g, the combination of Alpelisib and Tazemetostat induced tumor regression of Vaco481 CRC cells with a PIK3CA Q546P mutation and a CRC PDX harboring a PIK3CA E542K mutation.